PinnyPeptide

Colivelin vs DNSP-11

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Colivelin

Cognitive

Hybrid Humanin / ADNF peptide — high-potency neuroprotective agent for Alzheimer's research.

Peptide B

DNSP-11

Cognitive

Eleven-amino-acid peptide derived from the GDNF prodomain — neuroprotective for dopamine neurons.

Typical vial

10 mg

Typical dose

100-500 mcg

Half-life

~hours (longer than parent Humanin)

FDA status

Not FDA approved.

Typical vial

5 mg

Typical dose

Variable (research-specific) mcg

Half-life

Short; precise value uncharacterized

FDA status

Not FDA approved.

Colivelin effects

  • Femtomolar-range neuroprotection against amyloid-β toxicity
  • Activates STAT3 pro-survival signaling
  • Engages ADNF neurotrophic signaling
  • Attenuates cognitive deficits in Alzheimer's mouse models
  • Activity in ALS and stroke animal models

DNSP-11 effects

  • Dopaminergic neuroprotection in Parkinson's models
  • Increased dopamine production in dopaminergic neurons
  • Improved motor function in 6-OHDA and MPTP models
  • Mechanism distinct from full-length GDNF
  • Investigational for Parkinson's and related disorders

Colivelin side effects

  • Essentially uncharacterized in humans
  • Long-term safety data unavailable
  • Theoretical: off-target STAT3 activation effects
  • Injection-site reactions

DNSP-11 side effects

  • Essentially uncharacterized in humans
  • Possible local tissue effects with intracerebroventricular delivery
  • Theoretical: off-target effects on non-dopaminergic neurons
  • Injection-site reactions

Colivelin dosing ranges

Neuroprotection research (intranasal)

100-500 mcg · Once daily · Per research protocol

Subcutaneous research

100-500 mcg · Once daily · Per research protocol

DNSP-11 dosing ranges

Research / Parkinson's models (preclinical)

Variable per protocol · ICV or peripheral routes · Per research design

Full Colivelin guide → Full DNSP-11 guide →

Colivelin vs DNSP-11 — common questions

What is the difference between Colivelin and DNSP-11?

Colivelin: Hybrid Humanin / ADNF peptide — high-potency neuroprotective agent for Alzheimer's research. Typical dose 100-500 mcg. DNSP-11: Eleven-amino-acid peptide derived from the GDNF prodomain — neuroprotective for dopamine neurons. Typical dose Variable (research-specific) mcg. Both fall under the Cognitive category.

Can you stack Colivelin and DNSP-11?

Stacking Colivelin with DNSP-11 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Colivelin or DNSP-11?

Colivelin is typically dosed: Once daily for Neuroprotection research (intranasal); Once daily for Subcutaneous research. DNSP-11 is typically dosed: ICV or peripheral routes for Research / Parkinson's models (preclinical).

Are Colivelin and DNSP-11 FDA approved?

Colivelin: Not FDA approved. DNSP-11: Not FDA approved.

Related peptide comparisons

adamax vs colivelincolivelin vs dihexacolivelin vs p21colivelin vs pe22-28colivelin vs pinealonadamax vs dnsp-11

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free